Joergen Olsen

Title: Joergen Olsen: Innovator in FGF21 Derivatives

Introduction

Joergen Olsen is a notable inventor based in Vaerloese, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of FGF21 derivatives. With a total of 3 patents to his name, Olsen's work has the potential to impact medical treatments significantly.

Latest Patents

Olsen's latest patents focus on FGF21 derivatives and their uses. The invention relates to a derivative of an FGF21 protein that includes a cysteine residue at specific positions, particularly at positions 180 or 181 of mature human FGF21. These derivatives exhibit high potency towards FGF receptors. The invention also encompasses pharmaceutical compositions that include these FGF21 derivatives along with pharmaceutically acceptable excipients, as well as their medical applications.

Career Highlights

Joergen Olsen is currently associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk has allowed him to explore innovative solutions in the field of diabetes and obesity treatment through his research on FGF21.

Collaborations

Olsen has collaborated with notable colleagues such as Birgit Wieczorek and Tina Moeller Tagmose. These collaborations have further enriched his research and development efforts in the biotechnology sector.

Conclusion

Joergen Olsen's contributions to the field of FGF21 derivatives highlight his innovative spirit and dedication to advancing medical science. His work continues to pave the way for new therapeutic options in healthcare.